Polypeptide Biomarkers for Post-PCI Adverse Cardiac Event Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients who have undergone percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) face a significant long-term risk of major adverse cardiac events, including death, heart failure, and recurrent myocardial infarction, for which existing strategies are inadequate in identifying and mitigating the risk.
Innovation Solution
The use of polypeptides such as NAP-2, TGF-α, ErBb3, and inhibitors of cotaxin-3, cathepsin-S, DKK-1, follistatin, ST-2, GRO-α, IL-21, NOV, transferrin, TIMP-2, TNFαRI, TNFαRII, angiostatin, CCL25, ANGPTL4, and MMP-3 to identify patients at risk and administer nucleic acids or polypeptides to improve cardiac function by reducing scar size and tissue remodeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing risk identification strategies are used for STEMI patients post-PCI, then the diagnostic approach is simple and widely available, but the ability to identify patients at risk of major adverse cardiac events is insufficient
Solution Approach 1:
The patent uses polypeptide expression profiles as intermediary biomarkers to bridge the gap between simple clinical observation and accurate risk prediction. These polypeptides serve as mediators that translate complex pathological processes into measurable diagnostic signals, enabling precise risk identification without requiring complex imaging or invasive procedures.
Solution Approach 2:
The invention shifts from traditional clinical parameters to molecular parameter changes by measuring polypeptide expression levels. This parameter transformation enables detection of subtle pathological changes that precede major adverse cardiac events, significantly improving risk identification accuracy while maintaining diagnostic simplicity through blood-based assays.
2Reliability
If no specific treatment is administered to high-risk patients, then the treatment approach is simple, but the survivorship and cardiac function remain poor
Solution Approach 1:
The patent implements preliminary action by identifying high-risk patients before major adverse cardiac events occur and administering targeted polypeptide treatments in advance. This proactive approach modifies the disease course before irreversible damage happens, significantly improving survivorship and cardiac function outcomes through early intervention.
Solution Approach 2:
The invention converts the harmful effect of scar formation and tissue remodeling into a beneficial outcome by using polypeptide therapies that modulate these processes. Instead of allowing uncontrolled fibrosis and remodeling that lead to heart failure, the treatment harnesses these pathways to promote favorable tissue repair and protect against adverse remodeling, thereby improving cardiac function and survivorship.
3Reliability
If aggressive monitoring and treatment are applied to all STEMI patients, then the survivorship may improve, but the cost and complexity of care increases significantly
Solution Approach 1:
The patent applies local quality by tailoring the intensity of monitoring and treatment to individual patient risk profiles rather than applying uniform aggressive care to all patients. High-risk patients identified through polypeptide profiling receive targeted intensive management, while low-risk patients receive standard care, optimizing survivorship benefits while minimizing unnecessary complexity and resource utilization.
Data Source
AI summary
This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac evert as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.